Login to Your Account

Senate user fee bill presses FDA over foreign study data

By Mark McCarty
Regulatory Editor

Tuesday, May 9, 2017

A Senate committee will meet May 10 to mark up legislation for the FDA user fee programs, and one of the more significant features of the so-called manager's mark of the legislation is that it calls on the agency to facilitate the use of "foreign clinical trial data to minimize duplicative clinical trials."

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription